The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.
More news for Wednesday, May 4
By
Kimberly Bonvissuto
May 04, 2022
Occupancy trends up after omicron slump: Omega … AHCA / NCAL launches Diversity Executive Leadership Program … How to support older adults related to gun ownership decisions, suicide prevention …...
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
U.S. senate narrowly confirms Califf to head FDA
Feb 15, 2022
Califf briefly served as FDA commissioner toward the end of President Barack Obama’s administration.
Senate committee backs Califf nomination to head FDA
Jan 14, 2022
Among those who voted against Califf’s nomination were Democrats who expressed concerns about his links to pharmaceutical companies.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.